BioLineRx Ltd - Company Profile
Powered by 
All the data and insights you need on BioLineRx Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date BioLineRx Ltd Strategy Report
- Understand BioLineRx Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
BioLineRx Ltd (BioLineRx) is a clinical-stage biopharmaceutical company that focuses on the development of products related to cancer and immunology. Its pipeline product BL-8040 is for the treatment of acute myeloid leukemia (AML) and relapsed or refractory AML. The company’s other pipeline drug candidate AGI-134 is synthetic alpha-gal immunotherapy that finds application in the treatment of solid tumors. BioLineRx's only product BL-5010 is a novel medical device indicated for the non-surgical removal of skin lesions. BioLineRx is headquartered in Modi'in-Maccabim-Re'ut, Israel.
Headquarters
Israel
Address
Modi'In Technology Park, 2 Hama'Ayan Street, Modiin, 7177871
Website
www.biolinerx.com
Telephone
972 8 6429100
No of Employees
49
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BLRX (TLV)
Revenue (2022)
$4.8M
EPS
XYZ
Net Income (2022)
XYZ
-142.9%
(2022 vs 2021)
Market Cap*
$57.5M
Net Profit Margin (2022)
XYZ
0.0%
(2022 vs 2021)
* As of and is in US$
BioLineRx Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| - |
| BL-5010: |
| Skin Lesions |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company entered into an agreement with Guangzhou Gloria Biosciences Co for the development of motixafortide across all indications in Asia. |
| 2023 | Regulatory Approval | In September, the company received approval from the US FDA for APHEXDA (motixafortide) in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. |
| 2023 | Contracts/Agreements | In March, the company entered into a collaboration agreement with Washington University School of Medicine to evaluate Motixafortide for CD34+ hematopoietic stem cell mobilization for gene therapies in sickle cell disease. |
Competitor Comparison
| Key Parameters | BioLineRx Ltd | Leo Pharma AS | GlycoMimetics Inc | Genzyme Corp | Spexis AG |
|---|---|---|---|---|---|
| Headquarters | Israel | Denmark | United States of America | United States of America | Switzerland |
| City | Modiin | Ballerup | Rockville | Cambridge | Allschwil |
| State/Province | - | - | Maryland | Massachusetts | - |
| No. of Employees | 49 | 5,252 | 38 | 4,800 | - |
| Entity Type | Public | Private | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Aharon Schwartz, Ph.D. | Chairman | Executive Board | 2004 | 80 |
| Philip A. Serlin, CPA, MBA | Chief Executive Officer | Senior Management | 2016 | 62 |
| Mali Zeevi, CPA | Chief Financial Officer | Senior Management | 2016 | 47 |
| Tami Rachmilewitz, M.D | Chief Medical Officer | Senior Management | 2023 | 53 |
| Ella Sorani, Ph.D. | Chief Development Officer | Senior Management | 2021 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward